NCT05110807View on ClinicalTrials.gov

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2022

Conditions
Advanced Malignant Tumors
Interventions
DRUG

TQB3617

TQB3617 is a BET inhibitor.

Trial Locations (2)

31002

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

510060

RECRUITING

Sun Yat-sen University Cancer Cen, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY